82 citations
,
February 1989 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” This study found that in men with benign prostatic hyperplasia, a 3-month treatment with a long-acting GnRH agonist significantly reduced intraprostatic DHT and 3α-diol levels by about 90% and testosterone by about 75%.
May 2026 in “Journal of Assisted Reproduction and Genetics” In this study, researchers developed and tested a novel peptide, AMHR2BP, which mimics the function of Anti-Müllerian hormone to protect ovarian follicles in mice, showing promise for preserving ovarian health during chemotherapy without causing toxicity.
9 citations
,
January 1997 in “Gynecological Endocrinology” This review discusses the regulation of hair growth, causes of excessive androgen secretion, and current safe solutions for hyperandrogenism manifestations in women but reports no new clinical results.
6 citations
,
August 2009 in “Mini-reviews in Medicinal Chemistry” This review summarizes the structural and chemical characteristics of current and novel antiandrogenic drugs but reports no new clinical findings.
1 citations
,
October 2022 in “International journal of endocrinology” This study found that dihydrotestosterone treatment in female rats altered anterior pituitary gland gene expression, with significant repression of prolactin and inhibition of GnRH receptor gene expression, suggesting specific hormone production changes.